157 related articles for article (PubMed ID: 37504371)
21. Three hematological indexes that may serve as prognostic indicators in patients with primary, high-grade, appendicular osteosarcoma.
Hu K; Wang Z; Lin P; Wen Z; Ren H; Sun L; Li H; Li B; Wang S; Zhou X; Tengwang S; Xu L; Ye Z
Oncotarget; 2017 Jun; 8(26):43130-43139. PubMed ID: 28562345
[TBL] [Abstract][Full Text] [Related]
22. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.
Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K
Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460
[TBL] [Abstract][Full Text] [Related]
23. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
24. Pathological Fracture and Prognosis of High-Grade Osteosarcoma of the Extremities: An Analysis of 2,847 Consecutive Cooperative Osteosarcoma Study Group (COSS) Patients.
Kelley LM; Schlegel M; Hecker-Nolting S; Kevric M; Haller B; Rössig C; Reichardt P; Kager L; Kühne T; Gosheger G; Windhager R; Specht K; Rechl H; Tunn PU; Baumhoer D; Wirth T; Werner M; von Kalle T; Nathrath M; Burdach S; Bielack S; von Lüttichau I
J Clin Oncol; 2020 Mar; 38(8):823-833. PubMed ID: 31928458
[TBL] [Abstract][Full Text] [Related]
25. Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study.
Prabowo Y; Setiawan I; Kamal AF; Kodrat E; Labib Zufar ML
Int J Surg Oncol; 2021; 2021():8843325. PubMed ID: 33996154
[TBL] [Abstract][Full Text] [Related]
26. Tumor size and prognosis in aggressively treated osteosarcoma.
Bieling P; Rehan N; Winkler P; Helmke K; Maas R; Fuchs N; Bielack S; Heise U; Jurgens H; Treuner J; Romanowski R; Exner U; Kotz R; Winkler K
J Clin Oncol; 1996 Mar; 14(3):848-58. PubMed ID: 8622033
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.
Yang Q; Chen T; Yao Z; Zhang X
World J Surg Oncol; 2020 Jan; 18(1):24. PubMed ID: 32000789
[TBL] [Abstract][Full Text] [Related]
28. Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins?
Reddy KI; Wafa H; Gaston CL; Grimer RJ; Abudu AT; Jeys LM; Carter SR; Tillman RM
Bone Joint J; 2015 Jan; 97-B(1):115-20. PubMed ID: 25568424
[TBL] [Abstract][Full Text] [Related]
29. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
30. Survival and prognostic factors in Chinese patients with osteosarcoma: 13-year experience in 365 patients treated at a single institution.
Wang W; Yang J; Wang Y; Wang D; Han G; Jia J; Xu M; Bi W
Pathol Res Pract; 2017 Feb; 213(2):119-125. PubMed ID: 28040328
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in non-metastatic limb osteosarcoma: A 20-year experience of one center.
Tomer G; Cohen IJ; Kidron D; Katz K; Yosipovitch Z; Meller I; Zaizov R
Int J Oncol; 1999 Jul; 15(1):179-85. PubMed ID: 10375613
[TBL] [Abstract][Full Text] [Related]
33. Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt.
Morsy AM; Ahmed BM; Rezk KM; Ramadan IK; Aboelgheit AM; Eltyb HA; Abd Elbadee OM; El-Naggar MS
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e66-e78. PubMed ID: 31107367
[TBL] [Abstract][Full Text] [Related]
34. Correlation between the changes of serum COX 2, APE1, VEGF, TGF-β and TSGF levels and prognosis in patients with osteosarcoma before and after treatment.
Zhang Q; Dong G; Wang F; Ding W
J Cancer Res Ther; 2020; 16(2):335-342. PubMed ID: 32474521
[TBL] [Abstract][Full Text] [Related]
35. Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
Kim SH; Shin KH; Moon SH; Kong Y; Suh JS; Yang WI
J Surg Oncol; 2017 May; 115(6):752-759. PubMed ID: 28403564
[TBL] [Abstract][Full Text] [Related]
36. The prognostic significance of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in giant cell tumor of the extremities.
Chen Z; Zhao G; Chen F; Xia J; Jiang L
BMC Cancer; 2019 Apr; 19(1):329. PubMed ID: 30961549
[TBL] [Abstract][Full Text] [Related]
37. Influence of local recurrence on survival in patients with extremity osteosarcoma treated with neoadjuvant chemotherapy: the experience of a single institution with 44 patients.
Bacci G; Longhi A; Cesari M; Versari M; Bertoni F
Cancer; 2006 Jun; 106(12):2701-6. PubMed ID: 16691623
[TBL] [Abstract][Full Text] [Related]
38. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S; Bielack SS; Whelan J; Bernstein M; Hogendoorn P; Krailo MD; Gorlick R; Janeway KA; Ingleby FC; Anninga J; Antal I; Arndt C; Brown KLB; Butterfass-Bahloul T; Calaminus G; Capra M; Dhooge C; Eriksson M; Flanagan AM; Friedel G; Gebhardt MC; Gelderblom H; Goldsby R; Grier HE; Grimer R; Hawkins DS; Hecker-Nolting S; Sundby Hall K; Isakoff MS; Jovic G; Kühne T; Kager L; von Kalle T; Kabickova E; Lang S; Lau CC; Leavey PJ; Lessnick SL; Mascarenhas L; Mayer-Steinacker R; Meyers PA; Nagarajan R; Randall RL; Reichardt P; Renard M; Rechnitzer C; Schwartz CL; Strauss S; Teot L; Timmermann B; Sydes MR; Marina N
Eur J Cancer; 2019 Mar; 109():36-50. PubMed ID: 30685685
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.
Wang B; Tu J; Yin J; Zou C; Wang J; Huang G; Xie X; Shen J
Oncotarget; 2015 Nov; 6(35):38348-59. PubMed ID: 26435480
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.
Ferrari S; Bertoni F; Mercuri M; Picci P; Giacomini S; Longhi A; Bacci G
Ann Oncol; 2001 Aug; 12(8):1145-50. PubMed ID: 11583198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
